Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR+
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Financial Results
  • Stock Data
    • Analyst Coverage
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR+
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Dec 10, 2021 7:01am EST

XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

Dec 09, 2021 8:03am EST

XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners

Dec 02, 2021 7:00am EST

XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study

Nov 23, 2021 7:00am EST

XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

Nov 09, 2021 7:00am EST

XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering

Nov 04, 2021 2:48pm EDT

XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange

Nov 02, 2021 6:13pm EDT

XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange

Oct 15, 2021 5:38pm EDT

XORTX Therapeutics Announces Closing of US$12 Million Public Offering

Oct 14, 2021 5:30pm EDT

XORTX Announces Results from Mount Sinai’s COVID-19 Clinical Study

Oct 14, 2021 7:00am EDT

XORTX to Present at the LD Micro Main Event

  • arrow_back
  • 1…
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …18
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap